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ABSTRACT
Long noncoding RNAs (lncRNAs) are transcribed by genomic regions (exceeding 
200 nucleotides in length) that do not encode proteins. While the exquisite regulation 
of lncRNA transcription can provide signals of malignant transformation, lncRNAs 
control pleiotropic cancer phenotypes through interactions with other cellular 
molecules including DNA, protein, and RNA. Recent studies have demonstrated that 
dysregulation of lncRNAs is influential in proliferation, angiogenesis, metastasis, 
invasion, apoptosis, stemness, and genome instability in colorectal cancer (CRC), with 
consequent clinical implications. In this review, we explicate the roles of different 
lncRNAs in CRC, and the potential implications for their clinical application.
INTRODUCTION
Colorectal cancer is a frequently diagnosed and 
fatal malignancy worldwide, with nearly 1.4 million 
newly diagnosed cases in 2012 [1]. The conventional 
chemotherapeutic strategies for CRC involve the use of 
highly toxic drugs, which cause undesirable side-effects 
[2]. It is therefore important to identify both novel 
biomarkers and therapies for early diagnosis and improved 
treatment.
Recently, the genomics has identified unexpected 
non-protein coding regions of the genome. The list of 
long noncoding RNAs (lncRNAs), functionally defined 
as transcripts >200 nt in length with no protein-coding 
potential, continues to grow. Researchers have discovered 
many of these lncRNAs are uniquely expressed in 
differentiated tissues or specific cancer types. It is now 
established that lncRNAs are exquisitely controlled and 
are restricted to specific cell types to a greater degree 
than mRNA [3]. They frequently have evolutionarily 
conserved function, secondary structure, and regions 
of microhomology, despite minimal overall sequence 
similarity [4]. However, the functions of the vast majority 
of these transcripts remain unknown. Evidence supports 
the important role lncRNAs perform in CRC (Figure 1), 
via incompletely understood mechanisms. In this review, 
we comprehensively detail the functional roles of 
lncRNAs in maintaining the hallmarks of malignancy in 
colorectal cancer, and their potential clinical applications 
in the treatment of CRC (Table 1).
SUSTAINING PROLIFERATION
In normal tissue, the production and release of 
cellular growth signals is tightly controlled, ensuring 
homeostasis and balance in the cellular population. 
Review
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Dysregulation of such signaling leads to malignancy. 
Uncontrolled gene transcription with resultant protein 
production may increase cellular proliferation, but 
excess proliferative signaling may in turn trigger cellular 
senescence. Cancer cells may also sustain proliferation 
by evading growth suppressors. For instance, the RB 
protein is pivotal in negative control of the cell cycle 
and tumor progression. TP53 proteins control cellular 
division and prevent uncontrolled growth-and-division by 
activating apoptosis and preventing cell-cycle progression 
[5]. In recent years, the role of lncRNAs in sustaining 
proliferation of CRC cells has garnered great interest 
(Table 2).
LncRNA colon cancer-associated transcript 
1(CCAT1) is a recently discovered 2628 nucleotide-
lncRNA, located in the vicinity of c-Myc. He et al 
discovered that c-Myc could promote CCAT1 transcription 
by directly binding to its promoter region, and enhanced 
CCAT1 expression in CRC cells cells increased cell 
proliferation and invasion [6]. Moreover, Takahashi et al 
reported lncRNA Plasmacytoma variant translocation 1 
(PVT-1) expression is increased by amplification of 8q24 
Figure 1: The functions of lncRNA in colorectal cancer pathogenesis. LncRNAs have multiple functions in the context of 
colorectal cancer, including increasing proliferation, angiogenesis, metastasis, invasion, apoptosis, stemness, and genomic instability. Red 
arrows indicate promoted signaling pathways. Blue arrows indicate inhibited signaling pathways. Some LncRNAs have multiple functions 
(for example, CCAT2 promotes proliferation, metastasis, and genomic instability). Abbreviations: CCAT2: colon cancer-associated 
transcript 2; CCAT1: LncRNA colon cancer-associated transcript 1; BANCR: BRAF-activated lncRNA; TUG1: Taurine up-regulated gene 
1; FEZF1-AS1: long noncoding RNA FEZF1 antisense RNA1; CASC11: cancer susceptibility candidate 11; CRNDE: Colorectal Neoplasia 
Differentially Expressed; UCA1:urothelial carcinoma-associated 1 ;MEG3: maternally expressed gene 3; MALAT1: metastasis associated 
lung adenocarcinoma transcript 1; ANRIL: Antisense noncoding RNA in the INK4 locus; HOTAIR: Hox transcript antisense intergenic 
RNA; HOTTIP: ‘HOXA transcript at the distal tip’
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Table 1: A summary of lncRNAs involved in colorectal cancer development and progression
LncRNA In colorectal 
cancer, its 
expressions is:
Functions Reference
Colon Cancer Associated 
Transcript 1 (CCAT1)
Upregulated Promotes cellular proliferation, migration, and 
invasion.
[6]
Plasmacytoma variant 
translocation 1(PVT-1)
Upregulated Promotes proliferation and invasion. Knockdown of 
PVT-1 promotes apoptosis in colorectal cancer cell 
lines by activating the TGF-β signaling pathway.
[7]
Colorectal Neoplasia 
Differentially Expressed 
(CRNDE)
Upregulated Promotes colon cancer cell proliferation. [8, 9, 10]
Metastasis Associated Lung 
Adenocarcinoma Transcript 
1 (MALAT1)
Upregulated Promotes cellular proliferation, migration, and 
invasion via 1) binding to SFPQ and releasing 
oncogene PTBP2 from SFPQ/PTBP2 complex 2) 
increasing expression of AKAP-9 via promoting 
SRPK1-catalyzed SRSF1 phosphorylation in 
colorectal cancer cells.
[11, 12, 13]
ZNFX1 antisense RNA 1 
(ZFAS1)
Upregulated Silencing of ZFAS1 decreases CRC cell 
proliferation via G1-arrest of the cell cycle and 
decreasing CRC tumorigenicity. ZFAS1 acts as 
an oncogene in CRC via 1) destabilization of p53; 
2) interaction with CDK1/cyclin B1 complex 
leading to cell cycle progression and suppression 
of apoptosis.
[14, 15, 16, 17]
MYC-induced lncRNAs 
(MYCLo-1, MYCLo-2, 
MYCLo-3)
Upregulated Promotes MYC-modulated cell proliferation. 
MYCLo-1/-2 promote G1/S transition. MYCLo-3 
decreases cellular time spent in the S and G2 phases.
[18]
MYC-repressed lncRNAs 
(MYCLo-4, MYCLo-5, 
MYCLo-6)
Downregulated Inhibits MYC-enhanced cell proliferation. 
MYCLo-4/-6 increase G2 arrest. MYCLo-5 
decreases cellular populations in the S phase.
[19]
Antisense noncoding RNA in 
the INK4 locus (ANRIL)
Upregulated Promotes proliferation in a p15/p16-pRB pathway-
independent manner, and promotes cell invasion 
and migration.
[20, 61]
urothelial carcinoma-
associated 1 (UCA1)
Upregulated Activates proliferation, suppresses apoptosis 
and cell cycle progression of CRC cells. UCA1 
induces CRC migration and invasion and predicts 
poor prognosis.
[21, 22, 23]
BRAF-activated lncRNA 
(BANCR)
Downregulated Inhibits the proliferation in part through 
upregulation of p21, induces the epithelial-
mesenchymal transition (EMT) through an MEK/
extracellular signal-regulated kinase-dependent 
mechanism.
[24, 33]
Maternally expressed gene 3 
(MEG3)
Downregulated Inhibits CRC cell proliferation and is an 
independent predictor for overall survival.
[25]
LncRNA loc285194 Downregulated Suppresses tumor cell growth due to specific 
suppression of miR-211. Low expression of 
LOC285194 is associated with larger tumor size, 
higher tumor stage, more distant metastasis and 
poorer disease free survival.
[26, 27, 28]
(Continued )
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LncRNA In colorectal 
cancer, its 
expressions is:
Functions Reference
Loc554202 Downregulated Suppresses the cell proliferation, induces 
apoptosis, partly through activating specific 
caspase cleavage cascades, and inhibits CRC 
tumorigenesis.
[32]
LncRNA H19 Upregulated Promotes EMT in CRC. [34]
Hox transcript antisense 
intergenic RNA (HOTAIR)
Upregulated Indicates poorer prognosis, promotes migration and 
invasion, enhances CSC properties, promotes cellular 
proliferation, decreases the expression of E-cadherin 
and increases expression of vimentin and MMP9.
[36, 49]
HOTTIP(‘HOXA transcript 
at the distal tip’ )
Upregulated Predicts unfavorable prognosis for CRC patients. [37]
Taurine up-regulated gene 1 
(TUG1)
Upregulated Increases the invasive and metastatic ability of 
CRC cells through activating EMT process and 
TUG1 overexpression indicates poor survival rates 
and a higher risk for cancer metastasis.
[38]
FEZF1 antisense RNA1 
(FEZF1-AS1)
Upregulated Promotes migration and proliferation through 
activating the G1-S checkpoint
[39]
Cancer susceptibility 
candidate 11 (CASC11)
Upregulated Promotes CRC cell proliferation and metastasis by 
activation of WNT/β-catenin signaling.
[40]
91H Upregulated Promotes the proliferation, migration, and 
invasiveness of CRC cells.
[41]
LncRNA-CTD903 Downregulated Predicts favorable prognosis in CRC patients 
and suppresses invasion and migration through 
repressing Wnt/β-catenin signaling.
[42]
LncRNA TINCR Downregulated Suppresses CRC proliferation and metastasis by 
accelerating the cleavage of EpCAM and releases 
EpICD via activating WNT/β- catenin pathway.
[43]
ncRAN Downregulated Inhibits in vitro migration and invasion of CRC 
cells and predicts CRC patient outcome.
[44]
Colon cancer-associated 
transcript 2 (CCAT2)
Upregulated Promotes tumor growth, metastasis, and 
chromosomal instability. It functions as a WNT 
downstream target.
[46]
LncRNA-HIF2PUT Upregulated Promotes the HIF-2α expression and the CSC 
properties.
[48]
Lnc34a(locus mainly in the 
nucleus)
Upregulated Enhances CSC self-renewal and tumorigenesis and 
suppresses miR-34a expression.
[50]
LincRNA-p21 Downregulated Attenuates the viability, self-renewal, and 
glycolysis of CSCs.
[51]
LncRNA DANCR Upregulated Serves as a potential prognosis predictor for CRC 
prognosis, associates with TNM stage, histologic 
grade, and lymph node metastasis, and predicts 
shorter overall survival and disease-free survival 
time.
[52]
(Continued )
Oncotarget12521www.impactjournals.com/oncotarget
LncRNA In colorectal 
cancer, its 
expressions is:
Functions Reference
LncRNA FTX Upregulated Serves as an independent prognostic factor for 
CRC patients and is associated with differentiation 
grade, lymph vascular invasion, and clinical stage; 
indicates poorer overall survival.
[53]
Prostate cancer associated 
transcript 1(PCAT-1)
Upregulated Functions as an independent prognostic factor 
for CRC patient outcome and implicates poorer 
overall survival.
[54, 55]
RP11-462C24.1 Downregulated Serves as a prognosis indicator for CRC patients. 
Its down-regulation indicates increased distant 
metastasis and a poor disease-free survival.
[56]
PRNCR1 Upregulated Serves as a sensitive diagnostic biomarker of CRC. [57]
NEAT1 Upregulated Functions as s diagnostic and prognostic 
biomarker of overall survival in CRC, associates 
with tumor differentiation, invasion, metastasis 
and TNM stage and predicts shorter disease-free 
survival time and overall survival time.
[58, 59]
Table 2: LncRNAs involved in sustained proliferation of CRC
LncRNA In colorectal cancer, its 
expressions is:
Functions Reference
LncRNA Expression Functions Reference
CCAT1 Upregulated Promotes colon cancer cell proliferation. [6]
PVT-1 Upregulated Promote proliferation and invasion; 
Knockdown of PVT-1 promotes 
apoptosis in colorectal cancer cell lines 
by activating the TGF-β signalling 
pathway.
[7]
CRNDE Upregulated Promotes colon cancer cell proliferation. [8, 9, 10]
MALAT1 Upregulated Promotes cellular proliferation, 
migration, and invasion via 1) binding 
to SFPQ and releasing oncogene 
PTBP2 from SFPQ/PTBP2 complex 2) 
increasing expression of AKAP-9 via 
promoting SRPK1-catalyzed SRSF1 
phosphorylation in colorectal cancer 
cells.
[11, 12, 13]
ZFAS1 Upregulated Silencing of ZFAS1 decreases CRC 
cell proliferation via G1-arrest of 
the cell cycle and decreasing CRC 
tumorigenicity. ZFAS1 acts as an 
oncogene in CRC via 1) destabilization 
of p53; 2) interaction with CDK1/
cyclin B1 complex leading to cell 
cycle progression and suppression of 
apoptosis.
[14, 15, 16, 17]
(Continued )
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copy-number. CRC cells transfected with PVT-1 specific 
siRNA exhibited significant proliferative and invasive 
capability loss [7], supporting PVT-1 as a potential 
carcinogenic lncRNA in CRC. Another oncogenic lncRNA 
regulating CRC proliferation is Colorectal Neoplasia 
Differentially Expressed (CRNDE) [8], which is located 
on chromosome 16 of the human genome. It shares a bi-
directional promoter with iroquois homeobox 5 (IRX5), 
which is adjacent at the opposite strand. The expression of 
CRNDE is tissue-specific, and follows a temporal pattern. 
Rarely is CRNDE observed in adult colorectal mucosa, 
liver, and white blood cells, and increased CRNDE 
expression occurs in the testis, breast, and skin [9]. 
Additionally, CRNDE expression is significantly increased 
in several neoplastic diseases, including colorectal cancer. 
There are two existing CRNDE transcripts: cytoplasmic 
(fully spliced and free of intron sequences) and nuclear 
(the intron sequences) transcripts. Insulin, IGF1, and 
IGF2 do not increase or decrease cytoplasmic CRNDE 
transcripts, but decrease nuclear CRNDE transcripts via 
both the PI3K/Akt/mTOR and Raf/MAPK pathways. 
Knockdown of gVC-In4, a highly-conserved region of 
CRNDE, affects insulin signaling responses, as well as 
many genes associated with glucose/lipid metabolism. 
Several other insulin-regulated genes are affected by 
gVC-In4 knockdown as well. GLUT4, an insulin-
regulated glucose transporter, translocates to the plasma 
membrane, allowing intracellular glucose transport. 
LncRNA In colorectal cancer, its 
expressions is:
Functions Reference
MYC-induced 
lncRNAs 
(MYCLo-1, 
MYCLo-2, 
MYCLo-3)
Upregulated Promotes MYC-modulated cell 
proliferation. MYCLo-1/-2 promote 
G1/S transition. MYCLo-3 decreases 
cellular time spent in the S and G2 
phases
[18]
MYC-repressed 
lncRNAs 
(MYCLo-4, 
MYCLo-5, 
MYCLo-6)
Downregulated Inhibits MYC-enhanced cell 
proliferation. MYCLo-4/-6 increase 
G2 arrest. MYCLo-5 decreases cellular 
populations in the S phase.
[19]
ANRIL Upregulated Promotes proliferation in a p15/p16-
pRB pathway-independent manner.
[20]
UCA1 Upregulated Activates proliferation, suppresses 
apoptosis and cell cycle progression of 
CRC cells.
[21, 22, 23]
BANCR Downregulated Inhibits the proliferation in part through 
upregulation of p21
[24]
Maternally 
expressed gene 3 
(MEG3)
Downregulated Inhibits CRC cell proliferation and 
serves as an independent predictor for 
overall survival.
[25]
LncRNA 
loc285194
Downregulated Suppresses tumor cell growth due to 
specific suppression of miR-211. Low 
expression of LOC285194 shows larger 
tumor size, higher tumor stage, more 
distant metastasis and poorer disease 
free survival.
[26, 27, 28]
Loc554202 Downregulated Inhibits the cell proliferation and 
induces apoptosis, partly through 
activating specific caspase cleavage 
cascades.
[32]
Long noncoding 
RNA FEZF1 
antisense RNA1 
(FEZF1-AS1)
Upregulated Promotes proliferation through 
activating the G1-S checkpoint.
[39]
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CRNDE increases GLUT4 and MLXIPL transcription. 
gVC-In4 knockdown decreases glucose intake, thereby 
causing less lactate secretion. The increased expression 
of CRNDE nuclear transcripts promotes glucose 
metabolism, lactate secretion, and lipid synthesis in CRC 
cells. CRNDE nuclear transcripts influence upstream 
insulin/IGF signaling pathways. Thus CRNDE nuclear 
transcripts, which are inhibited by insulin, IGF1, and 
IGF2 via PI3K/Akt/mTOR and Raf/MAPK pathways, 
promote central metabolism [10]. Another well known 
lncRNA overexpressed in CRC is the human metastasis 
associated lung adenocarcinoma transcript 1 (MALAT1) 
[11]. Xu et al first reported that one fragment (6918 nt-
8441 nt, located at the 3’ end) of MALAT-1 is influential 
in the biological processes of cell proliferation, migration, 
and invasion [11]. Several mechanisms connect MALAT1 
to CRC cellular proliferation. It has been reported that 
MALAT1 overexpression enhances cell proliferation 
and migration in vitro, and promotes tumor growth 
and metastasis in nude mice, due to tumor suppressor 
gene SFPQ and proto-oncogene PTBP2. MALAT1 
binds SFPQ, releasing PTBP2 from the SFPQ/PTBP2 
complex. In turn, increased levels of SFPQ-detached 
PTBP2 promote cell proliferation and migration. In this 
sense, SFPQ mediates the regulatory effects of MALAT1 
[12]. Furthermore, MALAT1 interacts with both SRPK1 
and SRSF1. MALAT1 increases AKAP-9 expression by 
promoting SRPK1-catalyzed SRSF1 phosphorylation. 
After MALAT1 knockdown, overexpression of 
SRPK1 restored SRSF1 phosphorylation and AKAP-9 
expression, promoting cell proliferation, invasion, and 
migration in vitro. Conversely, SRPK1 knockdown after 
overexpression of MALAT1 in a CRC cell line reduced 
SRSF1 phosphorylation and AKAP-9 expression, and 
inhibited cell proliferation, invasion, and migration in 
vitro. These findings suggest MALAT1 increases AKAP-
9 expression by promoting SRPK1-catalyzed SRSF1 
phosphorylation in CRC cells [13].
Thorenoor et al recently profiled expression of 
disease-associated lncRNAs in CRC tumor tissues and 
identified ZFAS1 (zinc finger antisense 1), previously 
known to be a tumor suppressor gene in human breast 
cancer [14, 15] and oncogene in hepatocellular carcinoma 
[16], to be overexpressed in CRC tissue. ZFAS1 silencing 
reduced CRC cell proliferation through G1-arrest of cell 
cycle, and also tumorigenicity of CRC cells. Via RIP 
(RNA immunoprecitation) analysis, the authors identified 
Cyclin-dependent kinase 1 (CDK1) as an interacting 
partner of ZFAS1. Through bioinformatics analysis, the 
authors found that ZFAS1 could sponge miR-590-3p, 
which targets CDK1. The authors further demonstrated 
ZFAS1 activates CDK1 and cyclin B1. When ZFAS1 
is silenced, cyclin B1 is decreased. ZFAS1 silencing 
activates P53 and PARP cleavage, increasing CRC cell 
apoptosis. Taken together, ZFAS1 advances cell cycle 
progression and inhibits apoptosis, via activation of P53 
and CDK1/cyclin B1 complex, thus critical for CRC cell 
viability, cell cycle distribution, apoptosis, and colony 
formation [17]. Kim recently identified MYCLos as a key 
molecule in CRC cell cycle regulation and tumorigenesis, 
by influencing MYC target genes such as CDKN1A (p21) 
and CDKN2B (p15) [18]. RNA binding proteins HuR and 
hnRNPK are involved in the function of MYCLos, by 
respectively interacting with MYCLo-1 and MYCLo-2. 
Knockdown of MYCLo-2, differentially expressed in 
CRC, inhibits cancer transformation and tumorigenesis 
[18]. The same research group later characterized another 
three MYC-repressed lncRNAs named MYCLo-4, -5, 
and -6. The MYC-repressed MYCLos were proved to 
suppress cell cycle progression, and therefore inhibiting 
cell proliferation. Through screening all cell cycle-related 
genes affected by MYC and MYC-repressed MYCLos, the 
MYC-repressed gene GADD45A has been identified to be 
a target gene of MYCLo-4 and MYCLo-6 [19].
ANRIL is a lncRNA transcribed from the INK4 
locus, and encodes three tumor suppressor genes 
(p15, p16, and ARF). ANRIL represses p15 and p16, 
which positively regulate the pRB pathway, repressing 
senescence of normal human fibroblasts [20]. However, 
the role of ANRIL in cancer cell proliferation is not well 
understood. Naemura et al reported ANRIL increased 
proliferation of colorectal cancer HCT116 cells in two- 
and three-dimensional cultures. Silencing ANRIL by 
siRNA and retroviral-produced shRNA decreased HCT116 
cell proliferation in both two- and three-dimensional 
cultures. HCT116 cells depleted of ANRIL were arrested 
in the S phase of the cell cycle. Notably, silencing ANRIL 
did not activate expression of the INK4 locus. These 
observations suggest ANRIL increases proliferation of 
HCT116 cells in two- and three-dimensional cultures via 
p15/p16-pRB [20].
The lncRNA urothelial carcinoma-associated 1 
(UCA1) is significantly overexpressed in most tumor 
tissues and cancer cells. Han et al demonstrated UCA1 
levels were markedly increased in CRC tissues and cells 
compared to control, and the level of UCA1 expression 
was positively correlated with tumor size, poor histological 
differentiation, and increased tumor depth. Increased 
UCA1 expression carried significantly poorer prognosis 
and overexpression of UCA1 increases proliferation, and 
decreases apoptosis and cell cycle progression of CRC 
cells [21]. Ni et al further demonstrated that increased 
UCA1 expression was positively correlated to lymph 
node metastasis, distant metastasis, and tumor stage. 
Survival analysis revealed correlation between increased 
UCA1 expression and poor prognosis. Moreover, 
multivariate analysis identified UCA1 overexpression as 
an independent predictor for CRC. UCA1 knockdown 
significantly decreased CRC proliferation and metastasis. 
Flow cytometry assays demonstrated UCA1 silencing 
induced G0/G1 growth arrest and apoptosis of CRC 
cells. To further investigate the regulatory mechanisms 
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of UCA1, the authors identified that Ets-2 bound to the 
UCA1 core promoter using luciferase assays [22]. This 
observation suggested that UCA1 might be an important 
prognostic predictor in CRC and might be considered as a 
potential target for CRC diagnosis and gene therapy. More 
recently, Bian et al reported UCA1 sponged endogenous 
miR-204-5p, thereby inhibiting its activity in CRC, and 
identified CREB1 as a new target of miR-204-5p. The 
protein levels of CREB1 were significantly increased in 
CRCs, positively correlated with UCA1 expression, and 
negatively associated with survival. Taken together, Bian 
et al’s work demonstrated existence of a UCA1-miR-204-
5p-CREB1/BCL2/RAB22A regulatory network in CRC, 
supporting UCA1 and CREB1 as potential new oncogenes 
and prognostic factors for CRC [23].
LncRNAs may serve as tumor suppressors inhibiting 
CRC cellular proliferation. BRAF-activated non-coding 
RNA (BANCR) was first discovered during an RNA-
seq screen for transcripts influenced by the expression 
of the oncogene BRAFV600E. Shi et al demonstrated 
significantly decreased expression of BANCR in three 
colorectal cancer cell lines. Suppression of BANCR 
increases proliferation of colorectal cancer cells, partly 
via downregulation of p21 [24]. Maternally expressed 
gene 3 (MEG3) is another lncRNA that functions as a 
CRC proliferative suppressor. Yin et al reported decreased 
MEG3 levels correlated positively with low histological 
grade, increased tumor invasion, and advanced tumor 
node metastatic (TNM) stage CRC disease. Multivariate 
analyses revealed that MEG3 expression served as 
an independent predictor for overall survival. Further 
experiments demonstrated MEG3 overexpression 
significantly inhibited CRC cell proliferation both in vitro 
and in vivo [25].
Two lncRNAs have recently been identified as CRC 
proliferation inhibitors. Pasic et al first reported in 2010 
lncRNA loc285194 to be within a tumor suppressor unit 
in osteosarcoma, and suppressed tumor cell growth [26]. 
Another research group demonstrated LOC285194 to 
be decreased in tumor tissues and colorectal cancer cell 
lines compared to normal intestinal mucous cell lines. 
Additionally, low levels of LOC285194 were correlated 
with larger tumor size, increased tumor stage, more distant 
metastasis, and decreased disease-free survival [27]. Liu 
et al demonstrated loc285194 is a p53 transcription target, 
and ectopic expression of loc285194 inhibits tumor cell 
growth both in vitro and in vivo. Through deletion analysis, 
Liu et al identified an active region responsible for tumor 
cell growth inhibition within exon 4, which harbors two 
miR-211 binding sites. This loc285194-mediated growth 
inhibition is partially due to specific suppression of miR-
211 [28]. The second newly discovered CRC inhibitor 
lncRNA is loc554202. Loc554202 is a 2166-bp transcript 
on human chromosome 9p21.3, previously shown to be 
dysregulated in breast and lung cancer [29–31]. Ding et 
al reported expression of Loc554202 was significantly 
inhibited in CRC cell lines compared to normal human 
intestinal epithelial cell lines. Decreased loc554202 
expression was associated with advanced pathologic stage 
and a larger tumor size. Moreover, loc554202 expression 
decreased cellular proliferation, induced apoptosis in vitro, 
and hindered tumorigenesis in vivo, partly via specific 
caspase cleavage cascade activation [32].
ACTIVATING METASTASIS/INVASION 
PROGRAM
Although primary CRC can be treated by 
surgical resection, patient survival deteriorates once 
metastasis to vital organs (such as the liver or lungs) has 
occurred. Primary CRC develops progressively through 
accumulation of genetic mutations (e.g., APC, KRAS, p53, 
SMAD4, and PTEN) and epigenetic silencing of tumor 
suppressor genes. Mounting evidence suggests lncRNAs 
influence the invasive and metastatic potential of CRC 
(Figure 2 and Table 3). For instance, Guo et al. determined 
BANCR is overexpressed in CRC tissues, correlating 
with increased lymph node metastasis and tumor stage. 
While ectopic BANCR expression increased migration of 
human CRC Caco-2 cells, BANCR knockdown inhibited 
in vitro HCT116 cell migration [33], via induction of 
the epithelial-mesenchymal transition (EMT) through 
a MEK/extracellular signal-regulated kinase-dependent 
mechanism. These results suggest BANCR is essential 
for CRC metastasis, with great potential therapeutic value 
against CRC progression.
The lncRNA H19, a known oncogene in various 
cancer types, tumorigenesis and cancer progression. Liang 
et al recently characterized H19 as a novel regulator of 
epithelial-to-mesenchymal transition (EMT) in CRC. 
H19 is highly expressed in mesenchymal-like cancer 
cells and primary CRC tissues. Stable H19 expression 
promotes EMT progression and accelerates in vivo and 
in vitro tumor growth. Bioinformatics in combination 
with RIP analysis revealed H19 functions as a competing 
endogenous RNA (ceRNA) for miR-138 and miR-
200a, antagonizing their function, and activating their 
endogenous targets Vimentin, ZEB1, and ZEB2, all 
key marker genes of mesenchymal cells. In summary, 
lncRNA H19 is involved in EMT program as a competing 
endogenous RNA, ultimately contributing to CRC 
progression [34].
HOTAIR (the Hox transcript antisense intergenic 
RNA), is a lncRNA expressed from the developmental 
HOXC locus located on chromosome 12q13.13. Kogo 
et al reported HOTAIR expression levels were higher 
in cancerous tissues than in noncancerous tissues, and 
increased HOTAIR expression correlated positively 
with the liver metastasis. Moreover, patients expressing 
increased HOTAIR levels had poor prognosis. In a subset 
of 32 CRC specimens, gene set enrichment analysis 
using cDNA array data revealed a close correlation 
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between expression of HOTAIR and members of the 
PRC2 complex (SUZ12, EZH2, and H3K27me3) [35]. 
Wu et al more recently demonstrated HOTAIR was 
associated with epithelial-mesenchymal transition in CRC, 
reporting HOTAIR depletion increased the expression of 
E-cadherin while concomitantly decreasing expression 
of vimentin and MMP9 [36]. Upregulation of HOTAIR 
might be a critical element contributing to CRC metastatic 
progression. LncRNA taurine up-regulated gene 1 
(TUG1) has been reported to be correlated with cancer 
progression. Sun et al specifically analyzed TUG1 in the 
context of CRC, and demonstrated TUG1 expression 
was significantly increased in CRC cell lines, suggesting 
TUG1 downregulation may be a negative prognostic 
factor for CRC patients. TUG1 may increase the invasive 
and metastatic ability of CRC cells, at least in part through 
influencing the EMT process [38].
LncRNA FEZF1 antisense RNA1 (FEZF1-AS1) 
was recently corroborated to be significantly oveexpressed 
in human primary CRC, and is associated with CRC 
metastasis and poor prognosis. Moreover, suppression 
of FEZF1-AS1 expression significantly inhibited CRC 
cell proliferation, migration and invasiveness, suppressed 
S-phase entry in vitro, and repressed tumor growth and 
metastasis in vivo. FEZF1-AS1 overexpression increased 
malignant aspects of CRC cells. Dysregulation of FEZF1-
AS1 therefore participates in CRC tumorigenesis and 
progression [39]. Moreover, The overexpression of 
FEZF1-AS1 leads to significant cells reduction at G0/G1-
phase and increase in S-phase. Conversely, knockdown of 
FEZF1-AS1 does just the opposite. FEZF1-AS1 induces 
CRC cell proliferation by activating the G1-S checkpoint 
[39].
Cancer susceptibility candidate 11 (CASC11) is 
overexpressed in CRC tissues and is positively associated 
with tumor size, serosal invasion, lymph metastasis, and 
tumor-node-metastasis (TNM) stage. CASC11 promotes 
CRC cell proliferation and metastasis in vitro and in 
vivo. CASC11 increases expression of heterogeneous 
ribonucleoprotein K (hnRNP-K) and β-catenin nuclear 
accumulation, activating WNT/β-catenin signaling in 
CRC cells [40]. Additionally, c-Myc directly binds the 
promoter regions of CASC11, increasing promoter histone 
acetylation, augmenting CASC11 expression. CASC11 
has potential as a diagnostic biomarker, and may be an 
effective therapeutic against CRC. In addition, located 
on the H19/IGF2 locus (119.329 kbs long), 91H (H19 
antisense RNA) is a lncRNA which is overexpressed 
in CRC tissue and cell lines. 91H overexpression is 
correlated with increased metastasis and poor prognosis. 
Multivariate analysis demonstrates 91H expression is an 
independent prognostic and metastatic indicator of CRC. 
Figure 2: The regulation of metastasis by lncRNA. Red arrows indicate promoted signaling pathways; blue arrows indicate 
inhibited signaling pathways. Several lncRNAs (such as CCAT1, ANRIL, 91H, FEZF1-AS1, and ncRNA) have unknown mechanisms.
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Moreover, knockdown of 91H inhibited the proliferation, 
migration, and invasiveness of CRC cells [41].
Several lncRNAs that suppress metastasis were 
recently discovered. lncRNA-CTD903 is an independent 
predictor of favorable prognosis in CRC patients. After 
knockdown of CTD903 in CRC cell lines, CRC cells 
were noted to exhibit EMT-like appearance, decreased 
adherence ability, and increased invasion and migration 
characteristics. Inhibition of CTD903 increased Wnt/β-
catenin activation, increased transcription factors Twist 
and Snail expression, increased mesenchymal marker 
Vimentin, and decreased epithelial marker ZO-1. 
LncRNA-CTD903 is therefore likely a suppressor of 
metastasis in CRC via Wnt/β-catenin signaling repression 
[42]. Another suppressor of CRC metastasis is TINCR, a 
3.7 kb lncRNA. TINCR levels are negatively correlated 
with CRC progression, tumor growth, and metastasis 
(both in vivo and in vitro). During physiologic conditions, 
TINCR binds EpCAM. Loss of TINCR increases 
hydrolysis of EpCAM, increases release of EpICD, and 
activates the Wnt/β-catenin pathway. c-Myc decreases 
TINCR expression via repression of sp1-transcriptive 
activity, establishing a positive feedback loop controlling 
c-Myc and TINCR expression. Loss of TINCR expression 
promotes proliferation and metastasis in CRC, and is 
therefore a potential cancer suppressor gene [43]. ncRNA 
(non-coding RNA expressed in aggressive neuroblastoma) 
has previously been demonstrated to be overexpressed and 
Table 3: LncRNAs participate in metastasis/invasion-promoting programs of CRC
LncRNA In colorectal cancer, its 
expressions is:
Functions Reference
CCAT1 Upregulated Promotes cell migration and 
invasion.
[6]
BANCR Upregulated Induces EMT program through an 
MEK/extracellular signal-regulated 
kinase-dependent mechanism.
[33]
LncRNA H19 Upregulated Promotes EMT in CRC. [34]
HOTAIR Upregulated Promotes migration and invasion, 
decreases expression of E-cadherin, 
increases expression of vimentin 
and MMP9 and associates with 
poorer prognosis.
[36]
TUG1 Upregulated Increases the invasive and 
metastatic ability of CRC cells 
through activating EMT process
[38]
FEZF1-AS1 Upregulated Promotes migration. [39]
CASC11 Upregulated Promotes CRC cell metastasis, 
dependent on activation of WNT/β-
catenin signaling.
[40]
91H Upregulated Promotes proliferation, migration, 
and invasiveness of CRC cells.
[41]
LncRNA-CTD903 Downregulated Suppresses invasion and migration 
through repressing Wnt/β-catenin 
signaling.
[42]
LncRNA TINCR Downregulated Suppresses CRC proliferation 
and metastasis by accelerating the 
cleavage of EpCAM and releasing 
EpICD via activating WNT/β- 
catenin pathway.
[43]
ncRAN Downregulated Inhibits migration and invasion of 
CRC cells.
[44]
ANRIL Upregulated Promotes cell invasion and 
migration.
[61]
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associated with poor prognosis in human neuroblastoma, 
as well as bladder cancer. However, ncRAN is 
significantly decreased in CRC tumor tissue and CRC 
cell lines. Moreover, expression of ncRAN is inhibited 
in poorly differentiated or undifferentiated CRC tumors, 
and in CRC tumors with liver metastases. Multivariate 
analysis demonstrates decreased ncRAN expression is an 
independent predictor of overall survival. Taken together, 
these data suggest ncRAN may be a biomarker for early 
CRC metastasis, a prognostic indicator, and a therapeutic 
target against CRC [44].
GENOME INSTABILITY
All organisms require faithful propagation of 
genetic material and transmission into progeny cells, 
and avoidance of mutation propagation that may lead 
to genomic instability and aberrant cellular activity. 
Various DNA insults may occur by extrinsic factors 
such as ultraviolet (UV) radiation, ionizing radiation 
(IR), and numerous genotoxic chemicals [45]. In cancer 
cells, the rates of mutation increase due to breakdown 
of the genomic maintenance machinery. Despite cancer 
cell adaptation to this increased mutation rate, there is 
inevitably genomic instability within tumors themselves. 
Unfortunately, few investigations have identified potential 
lncRNAs involved in this process in CRC (Table 4). Ling 
et al reported that colon cancer-associated transcript 2 
(CCAT2), a novel lncRNA encompassing the rs6983267 
SNP, was overexpressed in microsatellite-stable colorectal 
cancer and promoted tumor growth, metastasis, and 
chromosomal instability. MYC, miR-17-5p, and miR-
20a are upregulated by CCAT2 via TCF7L2-mediated 
transcriptional regulation. The interaction between CCAT2 
and TCF7L2 enhances WNT signaling. As CCAT2 is a 
WNT downstream target, a feedback loop likely exists. 
SNP status affects CCAT2 expression, and allele G 
increases CCAT2 transcript production. CCAT2 activates 
WNT signaling by enhancing TCF7L2 transcriptional 
activity to increase MYC expression. CCAT2 transcription 
increases WNT target gene expression by binding TCF7L2 
and modulating its transcriptional activity. CCAT2 likely 
promotes chromosomal instability and tumor growth by 
activating WNT signaling and increasing MYC expression 
via activation of CDC25A, miR-17-5p, and miR-20a) [46].
STEMNESS
CRC has been recently identified to encompass 
a subset of cells with stem/progenitor cell features 
known as cancer stem cells (CSCs), which could lead 
to advanced tumors and a poor prognosis [47]. Because 
CSCs contribute to tumor-initiating potential, invasion, 
metastasis, resistance to traditional therapies, and eventual 
relapse, the CSC model explains clinical events previously 
a mystery, including therapy resistance, minimal 
residual disease, and tumor recurrence. However, the 
molecular hallmarks of CSCs in colorectal cancer remain 
unelucidated. While lncRNAs have been identified to be 
intimiately involved with various malignancies, their role 
in stemness maintenance in CRC remain the subject of 
intense study (Table 5).
The lncRNA “lncRNA-HIF2PUT” is a promoter 
upstream transcript of hypoxia-inducible factor-2α 
(HIF-2α) in CRC. The function of HIF-2α is closely 
connected with “stem cell-like” properties, and the 
function of promoter upstream transcripts (PROMPTs) 
is often associated with the adjacent protein-coding 
transcripts. lncRNA-HIF2PUT expression is correlated 
with HIF-2α levels in CRC tissues; knockdown of 
lncRNA-HIF2PUT blocked HIF-2α expression, and 
inhibited CSC properties in CRC cell lines. Knockdown 
of LncRNA-HIF2PUT via siRNA decreased expression 
of stemness genes, impaired colony formation, decreased 
spheroid formation ability, retarded migration, and 
decreased invasiveness [48]. The well-known lncRNA 
HOTAIR also participates in stemness maintenance in 
CRC. Dou et al demonstrated CD133(+)-shHOTAIR 
exhibited decreased cellular proliferation, migration, 
invasion, colony-forming properties of in vitro CRC cells, 
as well as decreased Vimentin expression with increased 
E-cadherin expression. Down-regulation of HOTAIR 
expression in CD133(+) CSCs markedly decreased tumor 
growth and lung metastasis in xenograft nude mice [49]. 
Therefore, HOTAIR may be a potential therapeutic target 
against CRC CSCs. In addition, the lncRNA Lnc34a is 
abundant in the CSCs of CRC, and initiates asymmetric 
division by directly targeting miR-34a, disrupting 
spatial balance. Lnc34a recruits Dnmt3a via PHB2 and 
HDAC1, methylating and deacetylating the miR-34a 
promoter simultaneously, epigenetically silencing miR-
34a expression independent of its upstream regulator, 
p53. Lnc34a levels increase CRC CSC self-renewal and 
CRC growth in xenograft models. Moreover, lnc34a is 
overexpressed in late-stage CRCs, causing epigenetic 
miR-34a silencing and CRC proliferation [50]. Wang et 
al recently identified lincRNA-p21 (large intergenic non-
coding RNA p21) is a potent suppressor of the stem-like 
traits of CSCs purified from both primary CRC tissues and 
cell lines. LincRNA-p21 inhibited β-catenin signaling, 
thereby decreasing viability, self-renewal, and glycolysis 
of CSCs in vitro. Administration of Ad-lnc-p21-MRE 
significantly decreased the self-renewal potential and 
tumorigenicity of CSCs in nude mice [51]. In this sense, 
lincRNA-p21 might be promising therapeutic against 
CSCs in CRC.
CLINICAL APPLICATION
LncRNAs emerge from a previously overlooked 
region of the genome, as a novel source of potentially 
useful biomarkers characterizing disease progression, 
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recurrence, and prognosis. The fact lncRNA expression 
levels are typically markedly increased or decreased 
depending upon disease state makes them ideal for 
useful clinical application. Most importantly, as we 
discover the mechanisms of their involvement in CRC, 
their applicability as therapeutics against CRC may be 
determined (Table 6).
LncRNAs have been intensively investigated for 
their role in predicting CRC prognosis. Liu et al reported 
that lncRNA DANCR expression was significantly 
increased in CRC tissues compared to adjacent normal 
tissues. Increased lncRNA DANCR expression was 
negatively correlated with TNM stage, histologic grade, 
and lymph node metastasis. Moreover, increased lncRNA 
DANCR expression was associated with decreased 
overall and disease-free survival for CRC patients [52]. 
Therefore, lncRNA DANCR expression holds potential as 
a prognosis predictor for CRC. FTX is another lncRNA 
with prognostic potential in CRC. FTX was significantly 
overexpressed in CRC tissues. Decreased FTX expression 
is associated with decreased differentiation grade, 
lymphatic vascular invasion, and clinical stage. Further 
multivariate analyses revealed that increased FTX levels 
serves as an independent prognostic factor for CRC patient 
survival [53].
LncRNA PCAT-1 (prostate cancer-associated 
ncRNA transcripts 1) is involved with human prostate 
cancer progression [54]. Ge et al demonstrated markedly 
increased PCAT-1 expression in CRC tissues. Increased 
PCAT-1 levels are associated with distant metastasis, and 
poorer overall survival. Multivariable Cox regression 
analysis identified PCAT-1 overexpression is an 
independent prognostic factor for CRC outcome. [55].
Some lncRNAs may also hold promise in the 
future as novel diagnostic biomarkers for CRC patients. 
lncRNA RP11-462C24.1 expression is decreased in CRC 
cancer tissues. Additionally, the levels of RP11-462C24.1 
are decreased in CRC patients with metastatic disease. 
Multivariate analysis identified RP11-462C24.1 to be an 
independent predictor of patient prognosis. Decreased 
RP11-462C24.1 levels were also associated with 
decreased disease-free survival. RP11-462C24.1 may be a 
novel prognostic and diagnostic marker for CRC [56]. In 
addition, prostate cancer non-coding RNA 1 (PRNCR1) 
has also been investigated as a diagnostic marker for 
CRC. Yang et al investigated the clinical significance and 
biological function of PRNCR1 in CRC. In a cohort of 
63 patients, PRNCR1 was significantly overexpressed in 
CRC tissues compared to adjacent control tissues, and 
PRNCR1 may be a sensitive diagnostic biomarker of CRC 
[57].
Liu et al demonstrated NEAT1 (nuclear-enriched 
abundant transcript 1) expression was increased in 
colorectal cancer, and positively associated with tumor 
differentiation, invasion, metastasis, and TNM stage. 
Increased NEAT1 expression levels were correlated 
with decreased patient survival. More importantly, Cox’s 
proportional hazards analysis demonstrated increased 
NEAT1 expression was an independent prognostic marker 
of poor CRC patient outcome. Therefore, NEAT1 may be 
a CRC prognostic indicator [58]. Wu et al analyzed the 
expression of NEAT1 in blood, matched primary tumor 
Table 4: Genome instability-related lncRNAs
LncRNA In colorectal cancer, its 
expressions is:
Functions Reference
CCAT2 Upregulated Increases chromosomal instability. [46]
Table 5: LncRNAs associated with stemness mantenance in CRC
lncRNA In colorectal cancer, its 
expressions is:
Functions Reference
LncRNA-HIF2PUT Upregulated Enhances the HIF-2α expression 
and promotes CSC properties.
[48]
LncRNA HOTAIR Upregulated Promotes CSC properties, increases 
cellular proliferation, migration, 
invasion, colony-forming.
[49]
Lnc34a(locus mainly in the 
nucleus)
Upregulated Enhances CSC self-renewal and 
tumorigenesis and suppresses miR-
34a expression.
[50]
LincRNA-p21 Downregulated Attenuates the viability, self-
renewal, and glycolysis of CSCs.
[51]
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tissues, para-tumor tissues, metastatic tissues, and immune 
cells from CRC patients and normal controls. Whole 
blood NEAT1 expression was significantly increased 
in colorectal cancer patients. Moreover, an elevated 
expression of NEAT1 was also seen in neutrophils from 
CRC patients [59]. In this sense, whole blood NEAT1 
expression may be a novel diagnostic, prognostic, and 
survival biomarker in colorectal cancer. Apart from 
that, Ren et al characterized the role of a new lncRNA 
HOTTIP (HOXA transcript at the distal tip) in CRC, and 
demonstrated HOTTIP was increased in CRC tissues, 
and positively correlated with clinical stage and distant 
metastasis. Multivariate analysis suggests HOTTIP 
overexpression to be an independent factor of poor CRC 
prognosis [37]. These lncRNAs are potentially valuable 
in clinical practice. However, there is still a long way for 
them to go from bench to bedside.
CONCLUSION AND PERSPECTIVES
More than 1.2 million patients are diagnosed 
annually with colorectal cancer, one of the most common 
human malignancies. Comprehension of the underlying 
molecular pathogenesis of the disease is urgently 
needed. It is now recognized that mutations within the 
noncoding genome are major determinants of human 
diseases [60]. LncRNAs, which occupy a large size of 
the noncoding genome, serve as important signals of 
specific cellular states, and can be employed to identify 
cellular pathologies such as cancer. In this review, we 
Table 6: Clinical application
LncRNA In colorectal cancer, its 
expressions is:
Functions Reference
DANCR Upregulated Serves as a potential prognosis 
predictor for CRC patients, 
associates with TNM stage, 
histologic grade, and lymph node 
metastasis, correlates with shorter 
overall survival and disease-free 
survival time.
[52]
FTX Upregulated Functions as an independent 
prognostic factor for CRC patients, 
associates with differentiation 
grade, lymph vascular invasion, 
and clinical stage, and predicts 
poorer overall survival.
[53]
PCAT-1 Upregulated Serves as an independent 
prognostic factor for CRC outcome 
and indicates poorer overall 
survival.
[54, 55]
RP11-462C24.1 Downregulated Serves as a prognosis indicator 
for CRC patients, associates with 
distant metastasis and poor disease-
free survival.
[56]
PRNCR1 Upregulated Proved to be a sensitive diagnostic 
biomarker of CRC.
[57]
NEAT1 Upregulated Serves as a diagnostic and 
prognostic biomarker of overall 
survival in CRC, associates with 
tumor differentiation, invasion, 
metastasis and TNM stage, and 
correlates with shorter disease-free 
survival time and overall survival 
time.
[58, 59]
HOTTIP Upregulated Predicts unfavorable prognosis for 
CRC patients.
[37]
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have carefully culled data supporting the use of lncRNAs 
for diagnostic, prognostic, and potentially therapeutic 
use for CRC patients. Currently, there remain significant 
gaps in our understanding of lncRNA function in CRC. 
The function of many lncRNAs in CRC development 
and progression remain unknown. Efforts devoted to 
elucidating the underlying molecular mechanisms of CRC-
specific lncRNAs are warranted and necessary. Systematic 
identification of potentially important lncRNAs central to 
CRC pathophysiology is necessary to advance the medical 
treatment of CRC for generations to come.
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